We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amphion Innovations Plc | LSE:AMP | London | Ordinary Share | GB00B0DJNP99 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.15 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
28/3/2014 09:13 | OK wiseacres what is it this time? Advance information about the US actions not known to the rest of us or just the normal attrition that befalls small caps who do not give their patient investors a lot of news? | caltonhill | |
12/3/2014 20:56 | I understand though that if they win judgement(s)the benefits to Amp will be quite considerable and this coupled with their stated 8p asset value could see a large uplift in the share price. Any comments on this ? | loobrush | |
12/3/2014 19:52 | it appears mighty odd when one is forced by judges to address only part of the problem. here in the uK my understanding of common law is that one is free to sue as one see's fit and that upholds one's rights versus having these moulded by large powerful concerns. Goodluck. | mac | |
04/3/2014 12:21 | For those wondering what is happening here with the various appeal trials concerning 402 & 502 patents. It would appear there are considerable discussions in progress with respect to forward strategy by Datatern. Recent oral arguments put forward by Datatern in November 2013 contested the final motion ( judgement ) in favour of SAP with regard to non pursuit of SAP & Microsoft clients. Even though the judges were sympathetic to the strength of the patents in question the main question was directed at Datatern's strategy of chasing each individual company who uses SAP & Microsoft software with the contested patent applications. The judges were of the opinion that Datatern should direct litigation towards SAP and Microsoft and file for infringement against these two main providers. Datatern's counter argument was each and every SAP and Microsoft client is then at liberty to use by degree the patents and license off to possible third parties without license terms to Datatern. In fact if Datatern agreed one off terms with SAP and Microsoft, Datatern would be deprived of third party license agreements and this figure is potentially huge. This is the main reason why this particular case is so prolonged plus the fact the technology is so complex for the judges to comprehend. Of course we are not patent lawyers but so far Datatern has successfully prosecuted numerous companies for patent infringement and not all of them resulted in license agreements. Negotiations are continuing behind the scenes and we all know it is the lawyers who gain the most from any protracted court proceedings. So far the judges have encouraged Datatern to open negotiations with SAP and Microsoft and possibly settle this prolonged and expensive dispute. If Datatern finally agree to talk with SAP and Microsoft an agreement or final settlement can be negotiated by agreeing a percentage in terms for third party use of this technology. | hoggar | |
27/2/2014 14:18 | New Orders Received in Medical Imaging Thu, 27th Feb 2014 07:00 RNS Number : 0459B Kromek Group PLC 27 February 2014 ? Embargoed until: 0700hrs, 27 February 2014 Kromek Group plc ("Kromek" or "the Company") New Orders Received in Medical Imaging Kromek, a supplier of patented radiation detection technologies to the medical, security and nuclear markets, announces that it has secured $845,000 of new orders to supply radiation detectors and integrated electronic components to a globally leading Original Equipment Manufacturer ('OEM') operating in the Dual Energy X-ray Bone Mineral Densitometry ('DEXA BMD') market. The total booking this fiscal year from this customer now exceeds $1.25 million. DEXA BMD is the most accurate imaging technique to diagnose the strength and health of bones, allowing clinicians to accurately detect, monitor and treat Osteoporosis in patients. DEXA BMD is another medical diagnostic imaging modality where improved x-ray detection and imaging detail helps early diagnostics and intervention, which enables healthcare providers to operate more efficiently and manage costs against a backdrop of global healthcare budget pressures. The new orders to supply detection components based on Kromek's Cadmium Zinc Telluride ('CZT') technology, are in addition to an existing contract the Company has in place with the OEM partner, in a global BMD market expected to surpass $895 million by 2017. Commenting on the announcement, Arnab Basu, CEO of Kromek, said: "This latest order from this existing OEM partner builds on an important international relationship as we continue to see growth through expanding our geographic reach, particularly in Asia. "Our work in BMD helps clinicians to detect and treat Osteoporosis earlier and is further validation of our technology and its capabilities in improving the efficacy of medical scanning technologies. This latest success adds to the encouraging progress we have seen in the wider medical imaging space, as evidenced by our announcement in November 2013 of a $990,000 contract to supply components to the nuclear medicine market, alongside the up to $5.3 million development contract we received in the x-ray CT scanning space. We have multiple blue-chip customers in the medical imaging sector and are seeing excellent traction in the adoption of our components. We look forward to announcing further progress in due course." -ends- | knowing | |
27/2/2014 13:49 | No view, just glad more buyers than sellers! | melodrama | |
27/2/2014 13:42 | Anyone an idea why the rise, is it the court case that is coming where they expect to win or an announcement due on one of their holdings? Looking at last accounts they said assets wee 8p a share but that they thought that they would be worth considerabley more. Any views ? | loobrush | |
27/2/2014 13:11 | What do you reckon, Datatern news? | melodrama | |
27/2/2014 12:53 | No you are not :-) | knowing | |
27/2/2014 12:39 | Yep, feels like i'm talking to myself | melodrama | |
27/2/2014 12:38 | Dum de dum, quiet here isn't Mel | melodrama | |
27/2/2014 12:07 | Aggressive buying eh what! | melodrama | |
28/1/2014 10:21 | These promissory Notes - It's hard to see how they can repay these without winning the Court cases. imo They are worth nearly as much as their stake in Kromek. | isis | |
23/12/2013 14:35 | Nice volume rise | melodrama | |
21/11/2013 12:49 | At the moment Kromek seems to be the only one with any value and the patents are a bit hit and miss to say the least. I don't understand what the Promissory Notes are either. AIM stocks are back in vogue at the moment though. | isis | |
21/11/2013 11:08 | 27% up - chasing here? | tomboyb | |
21/11/2013 10:47 | Looking perky on decent vols | melodrama | |
20/11/2013 11:45 | I would put the majority into KMK and if you wanted a bet a bit of speculation with a small amount - big risk big reward - buy a few AMP. | escapetohome | |
20/11/2013 11:42 | AMP's fortunes rest on more than just KMK but it's partner companies are reliant on many patent dispute outcomes plus they in turn burn cash like there's no tomorrow. AMP in it's turn is definitely short of cash so, as a newcomer, this means trying to put a realistic value on AMP is like tossing a coin. The question for me is is it better to buy into KMK directly or put that investment instead into AMP. Any thoughts would be welcome. | joan of arc | |
13/11/2013 10:10 | I see a Partner Company won a cash award. Unfortunately these Partner Co.'s burn so much cash it will hardly make a difference. As the Companies keep issuing share Amphion gets more diluted. The Court award if it goes ahead needs to be big. | isis | |
11/11/2013 12:20 | Thanks hoggars. | isis | |
11/11/2013 11:40 | A Federal hearing for Axcess Int was scheduled for the 2nd Dec 2013 regarding the litigation against Savi. However Axcess has now issued an appeal with the USPTO concerning certain aspects of patent 953. A final trial in number 1 court is set for 21st April 2014 and judgement will be set as regards full financial settlements for nine patent infringements and possibly another nine within the 953 patent of which Savi are contesting. Either way Axcess will be awarded damages from the court on 21st April 2014 the question is will they win all 18 claimed infringements against Savi. My own feeling is after the final trial Amphion will sell it's interest in Axcess to Radiant LLC who are putting up the $10mill for this litigation. | hoggar | |
11/11/2013 10:51 | Any idea when these Court Cases are due? | isis |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions